The second affiliated hospital of suzhou university
Welcome,         Profile    Billing    Logout  
 20 Trials 
28 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yang, Hua
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting
3
542
RoW
TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
01/27
12/28
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT06006689: Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Recruiting
2
228
RoW
Qishen Yiqi Dripping Pills placebo 3 bags, Placebo group, Low dose Qishen Yiqi Dripping Pills 3 bags, Low dose group, High dose Qishen Yiqi Dripping Pills 3 bags, High dose group
Tasly Pharmaceutical Group Co., Ltd
Diabetic Kidney Disease
09/25
09/25
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
902
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
Zeng, Yi
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
Chen, Rui
NCT04126590: Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Recruiting
1
39
RoW
KN044
Changchun Intellicrown Pharmaceutical Co. LTD
Advanced Solid Tumors
06/24
08/24
NCT05912296: A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Active, not recruiting
1
80
RoW
RBD7022, Placebo
Suzhou Ribo Life Science Co. Ltd.
Hyperlipemia
02/25
02/25
Zhuang, Zhixiang
NCT04416035: A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

Recruiting
3
608
RoW
TRS003, China-approved Bevacizumab, Carboplatin, Paclitaxel
Zhejiang Teruisi Pharmaceutical Inc.
Advanced Non-squamous Non-small-cell Lung Cancer
10/21
11/21
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting
2/3
374
RoW
SPH4336 Tablets 400mg, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
05/25
05/25
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
2
70
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Intrahepatic Cholangiocarcinoma (ICC)
05/26
12/26
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting
1/2
192
RoW
CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody), Best support care(BSC)
CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
06/24
06/38
JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Hourglass Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC
Recruiting
1/2
725
RoW
JSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor
12/24
12/26
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed
1
176
RoW
CMG901
Keymed Biosciences Co.Ltd
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
04/24
04/24
Liu, Chunfeng
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Recruiting
2
300
RoW
LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
04/25
07/25
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders

Recruiting
2
162
RoW
BAT4406F Injection, BAT4406F Placebos
Bio-Thera Solutions
Optic Neuromyelitis Spectrum Disease
05/25
05/26
Yang, Xiangdong
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting
4
466
RoW
Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638
The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.
Renal Insufficiency, Chronic
10/25
03/26
Zhan, Zhoubing
No trials found
Huang, Qianqian
No trials found
Xie, Yuyizi
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yang, Hua
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
TQB2102-III-01, NCT06561607: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

Not yet recruiting
3
542
RoW
TQB2102 for Injection, Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Breast Cancer
01/27
12/28
JSKN003-302, NCT06079983: JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

Not yet recruiting
3
400
RoW
JSKN003, Capecitabine tablets, Gemcitabine hydrochloride for injection, Vinorelbine tartrate injection, Paclitaxel for injection (albumin-bound type), Docetaxel injection, Eribulin mesylate injection
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Breast Cancer
04/25
03/29
FS-1502-III1-01, NCT05755048: FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
314
RoW
Investigational drug: Recombinant Anti-HER2 Humanized Monoclonal Antibody - Monomethyl Auristatin F Conjugates for Injection (FS-1502), Control drug: Trastuzumab emtansine (Kadcyla, T-DM1)
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Breast Cancer
07/25
01/26
NCT06006689: Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

Recruiting
2
228
RoW
Qishen Yiqi Dripping Pills placebo 3 bags, Placebo group, Low dose Qishen Yiqi Dripping Pills 3 bags, Low dose group, High dose Qishen Yiqi Dripping Pills 3 bags, High dose group
Tasly Pharmaceutical Group Co., Ltd
Diabetic Kidney Disease
09/25
09/25
NCT05438329: First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting
1/2
902
US, RoW
DB-1305/BNT325, DB-1305/BNT325 for Injection, Pembrolizumab, BNT327
DualityBio Inc., BioNTech SE
Advanced Solid Tumor
06/25
06/25
Zeng, Yi
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
Chen, Rui
NCT04126590: Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Recruiting
1
39
RoW
KN044
Changchun Intellicrown Pharmaceutical Co. LTD
Advanced Solid Tumors
06/24
08/24
NCT05912296: A Single and Multiple Ascending Doses Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RBD7022

Active, not recruiting
1
80
RoW
RBD7022, Placebo
Suzhou Ribo Life Science Co. Ltd.
Hyperlipemia
02/25
02/25
Zhuang, Zhixiang
NCT04416035: A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

Recruiting
3
608
RoW
TRS003, China-approved Bevacizumab, Carboplatin, Paclitaxel
Zhejiang Teruisi Pharmaceutical Inc.
Advanced Non-squamous Non-small-cell Lung Cancer
10/21
11/21
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer

Active, not recruiting
3
274
RoW
BPI-16350, placebo, Fulvestrant
Betta Pharmaceuticals Co., Ltd.
Breast Cancer
12/23
07/25
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer

Recruiting
3
360
RoW
PM8002, Nab-Paclitaxel, Placebo
Biotheus Inc.
Triple Negative Breast Cancer(TNBC)
07/27
07/28
NANORAY-312, NCT04892173 / 2021-002163-22: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Recruiting
3
500
Europe, Japan, US, RoW
JNJ-90301900 (NBTXR3), Functionalized hafnium oxide nanoparticles, NBTXR3, Cetuximab, Erbitux, Radiation Therapy
Johnson & Johnson Enterprise Innovation Inc., Nanobiotix SA
Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged
06/26
06/27
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Not yet recruiting
3
350
RoW
YK-209A tablet, Pemetrexed+carboplatin/Cisplatin
Suzhou Puhe Pharmaceutical Technology Co., LTD
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
07/25
12/26
NCT05744687: Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Recruiting
2/3
374
RoW
SPH4336 Tablets 400mg, SPH4336 Tablets Placebo
Shanghai Pharmaceuticals Holding Co., Ltd
Locally Advanced or Metastatic Breast Cancer
05/25
05/25
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Recruiting
2
70
RoW
ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Intrahepatic Cholangiocarcinoma (ICC)
05/26
12/26
TranStar102, NCT04495296: A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Recruiting
1/2
320
RoW
TST001, Oxaliplatin, Capecitabine, Paclitaxel, Gemcitabine, Cisplatin, Nivolumab
Suzhou Transcenta Therapeutics Co., Ltd., Bristol-Myers Squibb
Advanced Cancer
02/25
05/25
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Recruiting
1/2
192
RoW
CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice(Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody), Best support care(BSC)
CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University
Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma
06/24
06/38
JSKN003-102, NCT05744427: Safety and Tolerability of JSKN003 in Chinese Subjects With Advanced Solid Tumors

Hourglass Dec 2024 - Dec 2024 : Results for HER2-low, U/M BC
Recruiting
1/2
725
RoW
JSKN003
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Advanced Solid Tumor
12/24
12/26
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901

Completed
1
176
RoW
CMG901
Keymed Biosciences Co.Ltd
Advanced Solid Tumor, Gastric Cancer(Including Gastroesophageal Junction Adenocarcinoma), Pancreatic Cancer
04/24
04/24
Liu, Chunfeng
TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Remternetug, LY3372993, Placebo
Eli Lilly and Company
Alzheimer's Disease
04/29
10/30
TSL-CM-JSSPMFSL-Ⅲ, NCT06068465: A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis

Recruiting
3
248
RoW
pimavanserin tartrate, placebo
Tasly Pharmaceutical Group Co., Ltd
Parkinson's Disease Psychosis
06/25
01/26
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder

Completed
3
206
RoW
Daridorexant, Placebo
Jiangsu Simcere Pharmaceutical Co., Ltd.
Insomnia Disorder
04/24
05/24
TRAILBLAZER-ALZ 5, NCT05508789: A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

Recruiting
3
1500
Europe, RoW
Donanemab, (LY3002813), Placebo
Eli Lilly and Company
Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
04/27
04/27
NCT05686642: Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Recruiting
2
300
RoW
LT3001 Drug:high dose, Placebo, LT3001 Drug:low dose
Shanghai Pharmaceuticals Holding Co., Ltd
Acute Ischemic Stroke
04/25
07/25
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders

Recruiting
2
162
RoW
BAT4406F Injection, BAT4406F Placebos
Bio-Thera Solutions
Optic Neuromyelitis Spectrum Disease
05/25
05/26
Yang, Xiangdong
NCT04263922: Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3

Recruiting
4
466
RoW
Huaiqihuang granules, B12000050755, Valsartan capsule, H20030638
The First Affiliated Hospital of Dalian Medical University, Huazhong University of Science and Technology, LinkDoc Technology (Beijing) Co. Ltd.
Renal Insufficiency, Chronic
10/25
03/26
Zhan, Zhoubing
No trials found
Huang, Qianqian
No trials found
Xie, Yuyizi
No trials found

Download Options